In brief: C3, SSH, Axon
30 November, 2005 by Ruth BeranClinical Cell Culture's (ASX:CCE) co-founder Prof Fiona Wood will step down from the company's board on December 31. She will remain as a consultant, an R&D partner through her research vehicle the McComb Foundation, and a substantial shareholder.
Visiomed aims to raise $1.6m
30 November, 2005 by Ruth BeranPerth-based biomedical devices developer Visiomed Group (ASX:VSG) is aiming to raise AUD$1.6 million after costs through a placement of up to 90 million shares at $0.02 each.
Ambri on the hunt for M&A targets
30 November, 2005 by Ruth BeranSydney-based Ambri (ASX:ABI) is looking to merge with another medical diagnostics company with products that are closer to market.
The designer dairy cow
30 November, 2005 by Graeme O'NeillComparative genomics is helping speed up the identification of genes for desirable production traits in livestock, Graeme O'Neill reports.
Plants, proteins and proteomics
29 November, 2005 by Susan WilliamsonProfiling proteins is a challenging undertaking. But new research is providing new insights into protein structure and function, reports Susan Williamson.
Positive results for Peplin phase IIa 'sun spot' trial
28 November, 2005 by Helen SchullerPeplin (ASX:PEP) has reported positive results from its phase IIa clinical trial of its proprietary drug PEP005 Topical in actinic keratosis (AK), also known as solar keratosis, a skin condition which can develop into skin cancer.
US Army to participate in Neuren phase III trials
24 November, 2005 by Helen SchullerAuckland biopharma Neuren Pharmaceuticals (ASX:NEU) has executed a memorandum of understanding (MOU) with the Henry M. Jackson Foundation for the Advancement of Military Medicine for inclusion of US Army hospital sites in Neuren's phase III trial of its lead drug Glypromate.
Probiomics to commence flu vaccine trial
24 November, 2005 by Ruth BeranProbiomics' (ASX:PCC) shares increased by more than 25 per cent yesterday on news that the company will undertake a clinical trial to examine the ability of its proprietary probiotic strain PCC to boost the immune response to a vaccine for influenza.
Fast composter for city waste
23 November, 2005 by Graeme O'NeillResearchers from the Environmental Biotechnology Cooperative Research Centre (EBCRC) have successfully tested a, self-sustaining process that rapidly composts municipal solid wastes.
Norwood commences phase II cancer vaccine trial
21 November, 2005 by Graeme O'NeillMelbourne meditech Norwood Immunology (AIM:NIM) has recruited the first of 100 post-surgical melanoma patients into a phase II clinical trial of its thymus-rejuvenating technology, using the gonadotrophin releasing hormone (GNRH) analogue Lupron Depot.
National bioprospecting regulations released
21 November, 2005 by Ruth BeranThe Australian government has released new national environmental regulations to control 'bioprospecting' -- the search for new chemicals in living things that will have some medical or commercial use.
CSIRO abandons GM pea project
18 November, 2005 by Graeme O'NeillCSIRO Plant Industry researchers have abandoned a project to develop a genetically modified field pea with resistance to the pea weevil, Bruchus pisorum.
Novogen pleased by cancer drug results
18 November, 2005 by Ruth BeranTrials of Novogen's (ASX:NRT) anti-cancer drug phenoxodiol have shown it significantly delays tumour progression in men suffering from late-stage hormone refractory prostate cancer and produces anti-cancer responses in women with cervical cancer.
OPINION: Taking advantage of our clinical strengths
18 November, 2005 by Graeme BlackmanAustralia, take a bow -- you've proved you can compete in the global clinical trials market. But let's not get too complacent, writes Graeme Blackman.
REPORT: How we score on pharma R&D
18 November, 2005 by Ruth BeranRuth Beran wraps up a recent report that gives Australia a high rating against other major centres of pharma R&D.
